ID   L-NGC-5HT2 L-cells
AC   CVCL_6498
SY   L-NGC-5HT2
DR   CLO; CLO_0007368
DR   ATCC; CRL-10287
DR   Wikidata; Q54900908
RX   Patent=US5780485;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10287.
CC   Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Transfected with: HGNC; 5293; HTR2A.
CC   Discontinued: ATCC; CRL-10287; probable.
CC   Derived from site: In situ; Connective tissue; UBERON=UBERON_0002384.
CC   Cell type: Fibroblast; CL=CL_0000057.
CC   Breed/subspecies: C3H/An.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4536 ! L-M(TK-)
SX   Male
AG   100D
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 12
//
RX   Patent=US5780485;
RA   Gluchowski C., Forray C.C., Chiu G., Branchek T.A., Wetzel J.M.,
RA   Hartig P.R.;
RT   "Use of alpha1c specific compounds to treat benign prostatic
RT   hyperplasia.";
RL   Patent number US5780485, 14-Jul-1998.
//